Tolulope Olabintan, MD
Family Medicine · Mansfield, TXNPI 1558686105
Payments from drug & device makers
Across 283 payments — averaging $3152.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$600K
- AstraZeneca$162K
- Eli Lilly$102K
- Vertex$24K
- Novo Nordisk$562
- Viiv Healthcare Company$496
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,72298%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $600,448 |
| AstraZeneca | 3 | $162,302 |
| Eli Lilly | 3 | $101,718 |
| Vertex | 1 | $24,245 |
| Novo Nordisk | 30 | $562 |
| Viiv Healthcare Company | 23 | $496 |
| Merck | 17 | $382 |
| Johnson & Johnson | 19 | $327 |
| Lilly USA, LLC | 18 | $281 |
| Currax Pharmaceuticals LLC | 17 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $132 |
| Astellas Pharma US Inc | 6 | $107 |
| Eisai Inc. | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Amgen | 5 | $75 |
| Pfizer | 4 | $73 |
| Abbott | 3 | $73 |
| Hologic Sales And Service, LLC | 3 | $72 |
| GSK | 4 | $70 |
| Kowa Pharmaceuticals America, Inc. | 2 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Bayer | 2 | $43 |
| Shield Therapeutics Inc | 2 | $34 |
| Theratechnologies Inc. | 2 | $34 |
| Exact Sciences | 2 | $31 |
| Phadia US Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Linus Health, Inc. | 1 | $22 |
| Alk-abello, Inc | 1 | $21 |
| EMD Serono, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Gilead | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DELSTRIGO$101
How this compares
$892,188 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $92,556 |
| FarxigaDapagliflozin Propanediol | 18 | $23,406 |
| TrulicityDulaglutide | 11 | $21,886 |
| EliquisApixaban | 22 | $17,913 |
| MounjaroTirzepatide | 13 | $15,650 |
| Repatha SureclickEvolocumab | 16 | $10,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,472 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,969 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $6,703 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,144 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,316 |
| Amlodipine Besylate | 167 | $1,247 |
| Omeprazole | 65 | $1,210 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $999 |
| Estradiol | 27 | $995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $562 | $92,55676 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $281 | $37,53624 claims |
| AstraZenecaFarxiga | $162,302 | $23,40618 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $70 | $20,44131 claims |
| PfizerEliquis | $73 | $17,91322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Mansfield
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.